• Mesoblast posted FY2026 revenue of US$120.3 million, up from US$17.2 million a year earlier, on Ryoncil launch momentum.
• Net loss narrowed 44% to US$57.5 million; gross profit rose to US$103.6 million as product sales climbed to US$115.2 million.
• R&D expense increased to US$97.5 million; selling, general and administration costs rose to US$57.3 million.
• Net operating cash spend was US$43.8 million; cash and cash equivalents ended at US$103 million following a US$125 million credit-line facility.
• Management flagged Phase 3 treatment completion for rexlemestrocel-L in chronic low back pain, with top-line results expected mid-CY2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608262032PRIMZONEFULLFEED9816905) on August 27, 2026, and is solely responsible for the information contained therein.